A multi-centre study on the performance of the molecular genotyping platform ID RHD XT for resolving serological weak RhD phenotype in routine clinical practice

Vox Sang. 2020 Apr;115(3):241-248. doi: 10.1111/vox.12886. Epub 2020 Jan 7.

Abstract

Background and objectives: There is concern regarding the lack of prevention of unnecessary transfusion of RhD negative red cells and unnecessary administration of Rh immunoglobulin (RhIG) to pregnant women. In this study, performance of ID RHD XT, a genotyping assay for identification of six RHD allelic variants and human platelet antigens HPA-1a/1b was assessed.

Materials and methods: Whole blood samples presenting weak, discrepant or inconclusive D phenotype results were genotyped with ID RHD XT and compared to reference molecular tests. Candidacy for RhIG prophylaxis was determined by analysing samples from pregnant women. Hands-on time to complete the procedures was measured.

Results: Overall, 167 samples were tested (55 donors, 56 patients, 52 pregnant women and four newborns). Agreement between ID RHD XT and the reference method was 100% (51% weak D type 1, 2 or 3; 35·5% weak D Types 1, 2 or 3 not detected; 4% RHD deletion; 1% RHD*Pseudogene; 1% RHD*DIIIa-CE(3-7)-D; and 4% no amplification variant detected for RHD genotype; and 64% HPA-1a/a; 30% HPA-1a/b; and 3% HPA-1b/b for HPA-1 genotype). Call rate was 98·2%. ID RHD XT identified 40% of the pregnant women that would not have required RhIG prophylaxis. Overall hands-on time was 25-45 min to process a batch of 24 samples, and four hours for total assay time.

Conclusion: ID RHD XT yielded reproducible results for RHD typing in serologically weak D phenotype individuals. ID RHD XT was proven useful for the correct management of patients with RhD serological discrepancies and the rational use of RhIG in pregnancy.

Keywords: BLOODchip® ID; HPA-1; ID RHD XT; RhD; genotyping; red-blood-cells.

Publication types

  • Multicenter Study

MeSH terms

  • Alleles
  • Antigens, Human Platelet / genetics*
  • Female
  • Genotyping Techniques / methods*
  • Humans
  • Infant, Newborn
  • Integrin beta3
  • Pregnancy
  • Rh-Hr Blood-Group System / genetics*
  • Rho(D) Immune Globulin / genetics*

Substances

  • Antigens, Human Platelet
  • ITGB3 protein, human
  • Integrin beta3
  • Rh-Hr Blood-Group System
  • Rho(D) Immune Globulin
  • human platelet antigen 1b

Grants and funding